Candid Therapeutics
Candid Therapeutics is a biotechnology company developing T-cell engager (TCE) antibodies to treat autoimmune diseases. The company's lead candidates, CND106 and CND261, have shown promise in clinical trials and target specific B lymphocyte cell populations. Candid aims to be the first to bring these novel TCE therapies to market for autoimmune conditions.
Buy Funded Startups lists
Funding Round: Series A
Funding Amount: $370M
Date: 09-Sep-2024
Investors: Venrock Healthcare Capital Partners, Fairmount, TCGX, venBio Partners, Foresite Capital, Third Rock Ventures, Fidelity Management & Research Company, Samsara BioCapital, Qiming Venture Partners USA, OrbiMed, Boxer Capital, Redmile Group, Vida Ventures, Two River, Franklin Templeton, LifeSci Venture Partners, Mirae Asset Capital Life Science, Polaris Innovation Fund, Soleus Capital
Markets: Biotechnology, Immunotherapy, Autoimmune Diseases
HQ: San Diego, California, United States
Founded: 2024
Website: https://www.candidrx.com
LinkedIn: https://www.linkedin.com/company/candidrx
Crunchbase: https://www.crunchbase.com/organization/candid-therapeutics
Leave a Comment
Comments
No comments yet.